At a glance
- Originator AEterna Zentaris Inc
- Class Antineoplastics; Hormones
- Mechanism of Action DNA intercalators; Gonadotropin releasing hormone stimulants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Oct 2008 Discontinued - Preclinical for Cancer in Austria (IV)
- 06 Oct 2008 Discontinued - Preclinical for Cancer in USA (IV)
- 01 Jun 2006 This compound is still in active development